News

Europe’s firms ramp up R&D
Enlarge image

BusinessEU

Europe’s firms ramp up R&D

07.12.2012 - According to the 2011 EU Industrial R&D Investment Scoreboard, the 400 leading European companies invested about €132bn, a plus of 6.1% over 2009.

R&D investment by top EU companies recovered strongly in 2010. The annually published Scoreboard collects information on the top 1000 EU companies and 1000 non-EU companies investing the largest sums in research and development. What seems to be a positive trend as a first glance, shows some worrying trends at closer inspection. The study, which was commissioned by the European Commission, has shown that EU companies as a whole are lagging behind major competitors from the US and some Asian economies on R&D growth. While EU-based companies increased R&D expenditures by 6.1%, US-companies have spent 10% more. The increase was even larger in Taiwan (17.8%), South Korea (20.5%) and China(29.5%).

The global top 50, in terms of total R&D investment, includes 15 EU companies, 18 US firms and 13 from Japan. Two pharmaceutical companies occupied the top spots: Roche from Switzerland (€7.2bn) followed by Pfizer from the US (€7bn). A ray of light: A poll with some 190 mainly larger EU-companies surveyed in the Scoreboard revealed that they expect to maintain robust R&D investment increases (average 4% p.a.) over the next three years. This could be seen as a positive and stable trend for R&D investment growth, as observed before the 2008 economic and financial crises.

The Pharmaceuticals & Biotechnology sector has strengthened its position as the largest sector for R&D, its expenditures grew by 6.2% in 2010, slightly more than in 2009. The other two top sectors, Technology Hardware & Equipment and Automobiles & Parts are recovering from the significant reductions observed in the past Scoreboard (from -6.4% to 3.5% and from -11.6% to 0% respectively). Interestingly, all three sectors increased net sales more than they increased R&D investments.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science sees room for further improvement. „We need quick adoption and implementation of recent and up-coming European Commission proposals on the unitary patent, on standards, public procurement and risk capital“, she said. 

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/europes-firms-ramp-up-rd.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014